01What Stem Cell Therapy for Retinitis Pigmentosa Is
Retinitis Pigmentosa (RP) is a group of genetic conditions that affect the retina’s ability to respond to light. This inherited degenerative disease causes a gradual loss of vision, typically starting with reduced night vision and loss of peripheral vision, and can progress toward significant vision loss if untreated. The retina, the layer of light-sensing cells at the back of the eye, converts light into nerve impulses that travel via the optic nerve to the brain. In RP, the rod and cone cells of the retina degenerate — in most forms, rods (responsible for peripheral and night vision) are affected first, and when the more central areas of the retina are involved, color perception and central vision are affected as well.
Stem Cell Research
Researchers are studying whether implanting stem cells, delivered via retrobulbar or other methods, could help support patients with various eye-related disorders. As this area of research develops, protocols continue to be refined with the aim of slowing disease progression and supporting quality of life in a non-surgical way. Stem cells used in this research are generally autologous, sourced from the patient’s own bone marrow or adipose tissue — specifically adipose-derived stem cells (ASCs) and bone marrow-derived stem cells (BMSCs), sometimes used in combination depending on assessment.
Do You Know About Retinitis Pigmentosa?
Retinitis pigmentosa is an inherited eye disease that causes vision loss, typically beginning with night vision issues and a loss of peripheral vision, sometimes described as “tunnel vision.” Complete blindness is not the typical outcome for most patients. Onset is usually gradual and can begin in childhood.
RP is generally inherited and can result from mutations in more than 50 different genes, leading to progressive loss of rod and eventually cone photoreceptor cells. Diagnosis typically involves an eye exam looking for characteristic pigment deposits, supported by tests such as an electroretinogram, visual field testing, and genetic testing.
There is currently no cure for retinitis pigmentosa. Low vision aids, portable lighting, and orientation and mobility training are commonly used to help manage the condition, and vitamin A palmitate supplementation has been studied for its potential to slow progression in some patients. Vision prosthesis devices may be an option for some people with advanced disease. RP is estimated to affect roughly 1 in 4,000 people.
02Symptoms of Retinitis Pigmentosa
- Loss of night vision (night blindness)
- Gradual loss of peripheral (side) vision, sometimes called “tunnel vision”
- Loss of central vision in some patients
- Problems with color vision
03Types of Retinitis Pigmentosa
RP is a group of inherited conditions that cause progressive vision loss. Related types and conditions include:
- Usher syndrome
- Leber’s congenital amaurosis (LCA)
- Rod-cone disease
- Bardet-Biedl syndrome
04Causes of Retinitis Pigmentosa
RP results from mutations in more than 50 known genes, which carry instructions for proteins required within the retina’s photoreceptor cells. Some mutations prevent the cell from making a needed protein; others produce a protein that is toxic to the cell; and others still produce an abnormal protein that doesn’t function properly. In each case, the result is damage to the photoreceptors over time.
05How Retinitis Pigmentosa Is Diagnosed
Eye doctors can check for RP as part of a comprehensive dilated eye exam. Eye drops are used to widen the pupil so the doctor can examine the retina for signs of RP and other conditions. A visual field test may also be performed, checking peripheral vision by shining light in different areas of the visual field while the patient looks in a fixed direction, helping assess how well peripheral vision is functioning.
06How Stem Cell Therapy Is Approached as a Treatment for Retinitis Pigmentosa
Retinitis Pigmentosa causes a gradual loss of vision, typically beginning with reduced night vision and progressing to loss of peripheral vision. Some patients also experience difficulty with color perception. The rate of progression varies depending on the specific genetic cause. As night vision declines, adapting to darkness becomes more difficult, and central vision may be affected in some cases, sometimes described as macular dystrophy when the macula is involved.
Stem Cell Research for Retinitis Pigmentosa
Stem cell therapy for retinal degenerative disease remains an area of active research. Cell types studied include umbilical cord blood-derived stem cells (UCB-SC), umbilical cord mesenchymal stem cells (UCMSC), and bone marrow-derived mesenchymal stem cells (BM-MSC), which researchers are studying for their potential to support vision affected by photoreceptor and retinal neuron loss.
How Is Stem Cell Therapy for RP Being Studied?
An experimental stem cell-derived treatment intended to help preserve, and potentially support, vision in people with RP has reported a favorable safety profile in an ongoing Phase I/II clinical trial at the University of California, Irvine — one of the first stem-cell-derived treatments studied specifically for RP. Further results from this and similar studies are expected over time.
The approach generally involves injecting retinal progenitor cells into the vitreous, the gel-like substance in the center of the eye. Researchers hypothesize that these cells may produce proteins that help stabilize existing photoreceptors and slow degeneration, and possibly help preserve cone cells that have stopped functioning normally but have not fully degenerated. Cones are the photoreceptors responsible for reading, facial recognition, and vision in bright light.
Patient Care at Stem Cell Care India
- Counseling sessions take place in a dedicated recovery area at the facility.
- Patients are supported by medical staff throughout their stay.
- A minimum stay of 3 days is generally recommended.
07How It's Being Explored for Retinitis Pigmentosa
Conventional treatments can help manage certain eye conditions but generally cannot restore vision already lost. Research into stem cell-based approaches focuses on replacing damaged cells with healthy ones using the patient’s own cells (autologous), and researchers hope such approaches may eventually help address a range of vision impairments.
The approach studied generally involves injecting retinal progenitor cells into the vitreous. Researchers hypothesize these cells may produce proteins that help keep existing photoreceptors stable and slow further degeneration, and possibly help preserve cones that have stopped functioning but not fully degenerated.
08What the Retinitis Pigmentosa Treatment Process Looks Like
The stem cell treatment program at Stem Cell Care India typically spans 3 days:
Day 1 — Pick-up from Airport to Hospital — Consultation with the assigned doctor — Admission procedure — Clinical examination and recommended lab tests — Supportive therapy
Day 2 — Stem cell procedure — Supportive therapies — Physiotherapy
Day 3 — Supportive therapy — Physiotherapy — Discharge formalities — Airport drop-off
Note: Patients are asked to carry identification (passport, PAN card, or driving license) and hard copies of medical reports.
09Delivery Techniques Used in Stem Cell Therapy for Retinitis Pigmentosa
Stem cell implantation may be carried out through:
- Intravenous administration
- Intrathecal administration (lumbar puncture)
- Intramuscular administration
- Intraarterial administration
- Subcutaneous administration
- Surgical administration
10Changes Retinitis Pigmentosa Patients Sometimes Report
Areas where some patients undergoing this type of treatment, using umbilical cord-derived adult stem cells, have reported changes on follow-up include:
- Visual acuity
- Light perception
- Field of vision and night vision
- Color vision
- Nystagmus (reduced involuntary eye movement)
Some patients have also reported a slower rate of disease progression following treatment, though outcomes vary considerably and are not guaranteed for any individual.
11Is Stem Cell Therapy Safe for Retinitis Pigmentosa?
Stem cell therapy for Retinitis Pigmentosa is discussed only after an individual medical evaluation, and safety depends heavily on that case-by-case review rather than on the therapy in general. As with any medical intervention, mild and temporary reactions (such as soreness or fatigue at the injection or infusion site) are possible, and a full risk discussion happens as part of your evaluation. It is not offered to patients in an acute or unstable phase of Retinitis Pigmentosa, and it is never positioned as a substitute for guideline-based care from your treating specialist. For a fuller picture of how safety, accreditation, and quality standards are handled, see our Safety and Guarantees page.
12Who Might Consider a Retinitis Pigmentosa Discussion — and Who Should Not
May be reasonable to discuss
- A confirmed retinitis pigmentosa diagnosis, with the patient medically stable and not in an acute emergency
- Prior imaging, neurology, and treatment records available for review
- The injury is past its acute phase, with the patient in a stable, chronic-care stage
- Realistic expectations that any benefit would be supportive and investigational, not a cure
- Willingness to continue rehabilitation and follow-up care alongside this discussion
Generally not appropriate
- Acute or unstable neurological emergencies requiring immediate critical care
- Active untreated infection, uncontrolled bleeding disorder, or advanced organ failure
- An active, untreated malignancy that has not been cleared by an oncologist
- Pregnancy, or an expectation that the therapy will reverse or cure the underlying condition
- Unwillingness to share prior medical records or to be evaluated before proceeding
This list is general and educational — it is not a substitute for an individual medical evaluation of your case.
13What a Retinitis Pigmentosa Supportive-Care Discussion Involves
A supportive-care discussion for Retinitis Pigmentosa isn't a single conversation — it follows a defined sequence, so nothing is recommended before your specific case has been reviewed. In broad terms:
- Record review: Your existing diagnosis, imaging, lab work, and treatment history for Retinitis Pigmentosa are reviewed by the medical team first.
- Case-by-case medical evaluation: A physician assesses whether any further discussion is medically reasonable for your specific case — many enquiries end here with a clear "not appropriate" answer, which is a valid and expected outcome.
- Coordination with your specialist: Where a discussion proceeds, it is coordinated so it does not conflict with your ongoing care from your treating specialist.
- Transparent, written explanation: Any recommendation is explained in plain language, including its investigational status, realistic expectations, and that no outcome is guaranteed.
- Ongoing standard care continues: At every stage, your prescribed treatment for Retinitis Pigmentosa continues unless your own treating specialist changes it.
Nothing is scheduled or billed during this stage — it is a review and conversation, not a commitment.
14Our Approach to Retinitis Pigmentosa Care
We aim to provide patients considering this treatment with a safe, comfortable, and transparent experience, and to keep our services accessible without compromising on quality or care standards. We welcome both domestic and international patients, and we aim to stay in touch after treatment through a structured follow-up process to help monitor progress.
15Cost and How Stem Cell Therapy Compares for Retinitis Pigmentosa
Stem cell therapy costs in India are often more accessible than in many other countries, while following internationally recognized guidelines. Factors that can affect the cost include:
- Past medical conditions of the patient
- Current medical status of the patient
- Number of cells required for treatment
- BMI and overall physique of the patient
16What Influences Retinitis Pigmentosa Outcomes
As a relatively newer field in India, Stem Cell Care India has worked to build a track record informed by international protocols and specialist support. The clinic reviews its own case records for patients treated for Retinitis Pigmentosa, though outcomes vary between patients and no specific result can be guaranteed for any individual.
17Why Retinitis Pigmentosa Patients Consider Treatment in India
Considerations associated with stem cell therapy for RP include:
- Generally short-term hospitalization
- Described by the clinic as using an organic, minimally invasive approach with limited major side effects reported
- Potential for longer-lasting neuroregenerative and neuroprotective effects, according to ongoing research
- Direct delivery aimed at the affected area
- Comparatively more affordable than some alternatives
- Described as minimally invasive and less painful than more invasive procedures
18Quality Control in Cell Processing for Retinitis Pigmentosa Therapy
Stem Cell Care India follows a structured quality control process, including:
- Screening stem cell batches for contamination before processing
- Multi-stage screening for Gram-negative bacteria
- Testing processing media for mycoplasma and Gram bacteria
- Endotoxin screening for every batch against defined quality standards
- Screening cells after the final wash for aerobic and anaerobic microorganisms
- A Certificate of Analysis issued for every cell culture batch
19What Retinitis Pigmentosa Patients May Notice After Treatment
Some patients with retinal dystrophies and similar conditions who have received umbilical cord-derived adult stem cells have reported improvements in quality of life, including changes in visual acuity, night vision, and light perception, though outcomes vary and are not guaranteed for every patient.
20Retinitis Pigmentosa Patient Experiences
Florence L. Buse (California, US): I’ve been a patient of SCCI for three months and I’m seeing encouraging results. I was diagnosed with Retinitis Pigmentosa and knew stem cell treatment was an option, but it was too expensive where I live. The affordable treatment here has given me a lot of hope.
Thury Csongor (Erzsébet, Hungary): Treatment using stem cells at Stem Cell Care India has felt like an effective, more affordable option for Retinitis Pigmentosa. I’ve had treatment for a couple of months and I’m already seeing some results, with less discomfort than other approaches I’d tried.
Celina Wysocka (Zielona Góra, Poland): I have retinitis pigmentosa, a progressive and currently incurable condition. I was told I would eventually lose my sight. After starting stem cell treatment, I’ve noticed real changes in how clearly I can see the people and things around me. I’m grateful to the team at SCCI.
21Quality Certification for Retinitis Pigmentosa Therapy
Every patient receives third-party certification from an accredited laboratory confirming the quality and viability of the cells used in their treatment.
22Retinitis Pigmentosa Follow-Up Care
The team at Stem Cell Care India follows up with patients at one month, two months, and six months after treatment to assess progress. This also helps refine our protocols over time. Additional support is available if needed.
23Supportive Therapies Sometimes Used Alongside Retinitis Pigmentosa Treatment
Stem cell therapy is generally discussed as one part of a broader recovery plan rather than a stand-alone treatment. Supportive therapies sometimes used alongside it for retinitis pigmentosa include:
- Psychological support: To help address mood changes, anxiety, or emotional stress that can follow a retinitis pigmentosa.
- Speech therapy: For patients experiencing difficulty speaking, swallowing, or understanding language.
- Physiotherapy: To help rebuild movement, balance, and muscle strength.
- Hyperbaric oxygen therapy: Delivering oxygen at increased pressure, which is being explored as a supportive measure for tissue recovery.
- Acupuncture: Used by some patients as a complementary approach alongside conventional care.
- Rehabilitation therapy: Structured practice of daily tasks to support functional recovery.
- Occupational therapy: Support for relearning tasks such as dressing, eating, and writing.
- Nutrition therapy: Dietary guidance intended to support general recovery.
- Nerve Growth Factor (NGF) treatment: Supports the survival and growth of nerve cells; when discussed alongside stem cell therapy, it is explored for its potential to support nerve repair and overall brain recovery.
Any combination of these should be planned together with the treating medical team rather than pursued independently.
24Why Some International Retinitis Pigmentosa Patients Consider India
Retinitis pigmentosa affects people around the world, and many look to India for treatment options. The condition arises from gene mutations affecting healthy retinal function and progressively affects the eye’s light-sensitive cells, leading to night blindness and peripheral vision problems.
Factors International Patients Consider When Choosing India
- World-Class Medical Infrastructure: Modern diagnostic facilities, laboratories, and operating theatres.
- Experienced Ophthalmologists and Specialists: Practitioners experienced in managing RP using various approaches, including stem cell therapy.
- Access to Newer Approaches: Some Indian hospitals offer stem cell therapy, gene therapy, and retinal implants as options being studied for RP.
- More Affordable Treatment Costs: Generally lower than in many Western countries.
- Personalized Care Plans: Plans developed around the patient’s specific condition.
- Language Support: Interpreters and multilingual staff for international patients.
- Travel and Accommodation Assistance: Support with visas, travel, and nearby accommodation.
- Follow-Up Care: Post-treatment plans including virtual consultations and continued monitoring.
Patients considering treatment for RP in India travel from countries including the USA, UK, across Europe, the UAE, Thailand, Saudi Arabia, Nepal, and Tanzania, among others.
25Selected Retinitis Pigmentosa Research & Publications
- Human ESC-Derived RPE for Retinitis Pigmentosa: Phase I/II Lancet Trial — Schwartz SD et al. | The Lancet — https://doi.org/10.1016/S0140-6736(14)61376-3
- CPCB-RPE1 ESC-RPE Scaffold Implant for Retinal Dystrophies: Phase I/IIa — Kashani AH et al. | Science Translational Medicine — https://doi.org/10.1126/scitranslmed.aao4097
- iPSC-Derived Photoreceptor Progenitors for RP: 3D Organoid Differentiation — Mandai M et al. | Stem Cell Reports — https://doi.org/10.1016/j.stemcr.2017.01.023
- Exosome Therapy for Photoreceptor Degeneration: miRNA-Mediated Neuroprotection — Bhansali A et al. | Journal of Controlled Release — https://doi.org/10.1016/j.jconrel.2020.04.034
- Subretinal BM-MSC Transplantation in RP: Phase I Clinical Results — Siqueira RC et al. | Clinics (Sao Paulo) — https://doi.org/10.6061/clinics/2015(01)03
- MSC-Secreted CNTF and BDNF Preserve Photoreceptors in RP Animal Models — Caicedo A et al. | Stem Cell Reviews and Reports — https://doi.org/10.1007/s12015-014-9518-6
- Gene Therapy Combined with iPSC-RPE for Advanced Retinal Degeneration — Dalkara D et al. | Science Translational Medicine — https://doi.org/10.1126/scitranslmed.3005765
- Long-Term Safety of Subretinal Cell Therapy in Inherited Retinal Dystrophies — da Cruz L et al. | Nature Biotechnology — https://doi.org/10.1038/nbt.4114
- Human Neural Progenitor Cells Rescue Photoreceptors in Rodent RP Models — Gamm DM et al. | Investigative Ophthalmology & Visual Science — https://doi.org/10.1167/iovs.06-0654
- Photoreceptor Rescue by MSC via Anti-Apoptotic PEDF and VEGF Secretion — Johnson TV et al. | Molecular Therapy — https://doi.org/10.1038/mt.2009.262
Not sure if this applies to your case?
Share your diagnosis and reports, and our medical team will get back to you with a free, doctor-reviewed opinion on Retinitis Pigmentosa — no obligation.
- Reviewed by our in-house medical team
- Doctor-reviewed reply within 24–48 hours
- No cost and no obligation to proceed
- Your information is kept confidential
Get Your Free Evaluation
Frequently Asked Questions
Yes. Adults aged 20-39 are generally advised to have checkups every 3-5 years, adults 40-64 every 2-4 years, and those over 65 once a year. People with diabetes, a strong family history of glaucoma, or other high-risk conditions should have annual checkups regardless of age.
There is no scientific evidence that these devices emit harmful rays, though long screen time can cause fatigue, so periodic breaks are recommended.
These can be a sign of retinal issues, and it is best to see a doctor as soon as possible.
This is generally due to presbyopia, the natural age-related decline in the eye’s ability to focus on nearby objects.
Some conditions, such as glaucoma, are linked to genetic factors, while others, like corneal damage from injury, are related to environmental causes.
A whole eye currently cannot be transplanted, though part of the eye may be replaced when a suitable donor is available.
Stem cells are undifferentiated cells that can develop into different specialized cell types under the right signals. In eye disorders, researchers have studied their potential to influence the development of photoreceptor, rod and cone, and optic nerve cells.
RP is an inherited condition that causes gradual vision loss, including night vision and peripheral vision, as the retina’s photosensitive cells are progressively affected — typically rod cells first, followed by cone cells.
RP is caused by mutations in one or more of over 50 genes. External factors can influence the rate of progression but do not cause the underlying condition. Various gene mutations cause the eye’s photoreceptor cells to fail, leading to gradual retinal degeneration.
Yes, it can be passed from parents to children. If a parent carries a dominant gene for the condition, a child has roughly a 1 in 2 chance of inheriting it; for a recessive gene carried by both parents, the chance is roughly 1 in 4.
Symptoms can appear as early as childhood and vary in pattern and severity, but commonly include reduced night vision, blurred vision, inconsistent color differentiation, tunnel vision, and photophobia (increased sensitivity to bright light).
RP is generally associated with three main effects: night blindness, tunnel vision, and reduced clarity of color and detail vision.
Medically reviewed by the Stem Cell Care India clinical team. Last reviewed 2 September 2026. Written by Nishat Arfin · Scientific review by Tabish Iqbal · Medically approved by the Stem Cell Care India Medical Team.
Investigational-status disclaimer. This content is for informational and educational purposes only. Stem cell therapy for Retinitis Pigmentosa is considered investigational under current medical guidelines in India and is not FDA-approved. No guarantees or claims of cure are made. Results vary from patient to patient. Please consult a qualified healthcare professional before making any medical decisions.